Why BioCryst Stock Is Crushing It Today

Keith Speights, The Motley Fool
·2-min read
Why BioCryst Stock Is Crushing It Today

Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) were soaring 16.8% higher as of 11:44 a.m. EST on Friday. The big jump came after the drugmaker announced Food and Drug Administration (FDA) approval of Orladeyo (berotralstat) to prevent hereditary angioedema (HAE) attacks in adults and children ages 12 and up. BioCryst's market cap stood at close to $900 million before the FDA approval was announced.